Component: (Network and Table)
Network
00200 - Statement - Consolidated Statements of Operations
(http://www.onconova.com/role/StatementConsolidatedStatementsOfOperations)
Table(Implied)
Slicers (applies to each fact value in each table cell)
Reporting Entity [Axis]0001130598 (http://www.sec.gov/CIK)
Consolidated Statements of OperationsPeriod [Axis]
2016-01-01 - 2016-12-31
2015-01-01 - 2015-12-31
Consolidated Statements of Operations
 
 
Revenue
5,546,000  
11,456,000  
Operating expenses:
 
 
General and administrative
9,178,000  
9,533,000  
Research and development
20,071,000  
25,895,000  
Total operating expenses
29,249,000  
 
35,428,000  
 
Loss from operations
(23,703,000) 
 
(23,972,000) 
 
Change in fair value of warrant liability
3,988,000  
 
Other income, net
62,000  
(35,000) 
Net loss before income taxes
(19,653,000) 
 
(24,007,000) 
 
Income taxes
14,000  
16,000  
Net loss
(19,667,000) 
 
(24,023,000) 
 
Net loss attributable to non-controlling interest
 
44,000  
Net loss attributable to Onconova Therapeutics, Inc.
(19,667,000) 
 
(23,979,000) 
 
Net loss per share of common stock, basic and diluted (in dollars per share)
(4.44) 
(10.54) 
Basic and diluted weighted average shares outstanding (in shares)
4,426,639  
2,273,976